Scarica l'app Stockscreener
21.20
3.42%
-0.75
Dopo l'orario di chiusura:
21.20
Precedente Chiudi:
$21.95
Aprire:
$21.87
Volume 24 ore:
183.61K
Relative Volume:
0.38
Capitalizzazione di mercato:
$1.04B
Reddito:
-
Utile/perdita netta:
$-85.21M
Rapporto P/E:
-11.22
EPS:
-1.89
Flusso di cassa netto:
$-68.53M
1 W Prestazione:
-6.44%
1M Prestazione:
-1.40%
6M Prestazione:
-3.02%
1 anno Prestazione:
-15.27%
Intervallo 1D:
$21.04
$22.45
Intervallo di 1 settimana:
$21.04
$23.41
Portata 52W:
$13.30
$30.03
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Nome
Enliven Therapeutics Inc
Settore
Industria
Telefono
720-647-8519
Indirizzo
6200 LOOKOUT ROAD, BOULDER
Confronta ELVN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
21.20 | 1.29B | 0 | -85.21M | -68.53M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-16 | Iniziato | Goldman | Buy |
| 2024-12-13 | Iniziato | BTIG Research | Buy |
| 2024-09-09 | Iniziato | H.C. Wainwright | Buy |
| 2024-06-11 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-09 | Iniziato | Mizuho | Buy |
| 2023-03-29 | Iniziato | Jefferies | Buy |
Mostra tutto
Enliven Therapeutics Inc Borsa (ELVN) Ultime notizie
How does Enliven Therapeutics Inc. generate profit in a changing economyStay informed with expert market forecasts - jammulinksnews.com
What is the risk reward ratio of investing in Enliven Therapeutics Inc. stockNavigate market shifts with confidence - jammulinksnews.com
Is it the right time to buy Enliven Therapeutics Inc. stockExceptional gains - jammulinksnews.com
What catalysts could drive Enliven Therapeutics Inc. stock higher in 2025High-profit stock alerts - jammulinksnews.com
Should I hold or sell Enliven Therapeutics Inc. stock in 2025Build a strong portfolio for growth and safety - jammulinksnews.com
Sectors Driving Future Growth for Enliven Therapeutics Inc. StockWeekly Double Return List - Newser
Is Enliven Therapeutics Inc. Stock a Smart Buy in 2025 Investment Analysis InsideInstant Stock Updates - Newser
How Enliven Therapeutics Inc. stock performs during market volatilityFree Stock Tips Group - Newser
Is Enliven Therapeutics Inc. a Top Dividend Stock to Watch in 2025Free Trading Group - Newser
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Position Trimmed by New York State Common Retirement Fund - Defense World
Why Enliven Therapeutics Inc. stock attracts strong analyst attentionProfessional Stock Screener - Newser
What drives Enliven Therapeutics Inc. stock priceTremendous wealth creation - PrintWeekIndia
What risks could impact Enliven Therapeutics Inc. stock performanceMarket-beating returns - jammulinksnews.com
Will Enliven Therapeutics Inc. stock split in the near futureMoney Making Low Risk Plans - Newser
Polis encourages life-sciences companies to move to Colorado - BizWest
Enliven Therapeutics Inc. Stock Analysis and ForecastFree Wealth Planning Blueprint - Autocar Professional
BlackRock, Inc. Reduces Stake in Enliven Therapeutics Inc. - GuruFocus
What analysts say about Enliven Therapeutics Inc. stockOutstanding investment returns - Autocar Professional
Is Enliven Therapeutics Inc. a good long term investmentTriple-digit growth rates - Autocar Professional
Enliven Therapeutics CSO sells $278k in shares - Investing.com Australia
Enliven Therapeutics CSO sells $278k in shares By Investing.com - Investing.com India
Enliven Therapeutics’ Promising CML Study Update: What Investors Need to Know - MSN
Samuel Kintz Sells 12,500 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock - Defense World
Can Enliven Therapeutics, Inc. (ELVN) Climb 75.66% to Reach the Level Wall Street Analysts Expect? - MSN
Enliven Therapeutics’ Promising Phase 1a/1b Study on ELVN-002 in HER2+ Cancers - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Enliven Therapeutics (ELVN) - The Globe and Mail
Enliven Therapeutics Inc Azioni (ELVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.97%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):